Drug intelligence / Profile preview

Evolysse

Development stage: Unknown
Lead developer: Symatese
Modality: Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
Administration: Intradermal

Overview

Evolysse is a collection of injectable hyaluronic acid (HA) treatments developed by Symatese and distributed by Evolus. It utilizes Cold-X Technology, which preserves the natural structure of HA for natural-looking results. Evolysse is primarily used to correct moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds, in adults 22 years and older. The initial formulations include Evolysse Form and Evolysse Smooth, both of which provide results lasting up to 12 months.

Brand names: Evolysse

Beyond the preview

Go deeper on Evolysse.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evolysse.

Explore the full profile